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for	 measuring	 prothrombin	 time	 (PT)	 and	 activated	 partial	 thromboplastin	 time	
(aPTT).
Methods:	 PT	 Rec,	 PT	Owren,	 aPTT,	 aPTT	 Lupus	 and	 aPTT	 Screen	 assays	 (Roche	
Diagnostics)	 were	 evaluated	 on	 cobas t 711 and cobas t	 511	 analysers	 (Roche	
Diagnostics)	at	four	European	centres.	Analytical	performance	and	method	compari-
sons	 with	 relevant	 commercially	 available	 assays	 were	 performed	 to	 Clinical	
Laboratory	Standards	Institute	guidelines	using	residual	anonymized	samples.	Lot-	to-	




good	 agreement	 between	 each	 assay	 (cobas t	 711)	 and	 respective	 comparator	
method	 (Pearson’s	 r:	 0.964-	0.999,	n	>	120	 samples/assay/site).	Passing–Bablok	 re-
gression	analyses	demonstrated	equivalence	of	 the	 two	cobas t	platforms	 for	use	
with	each	assay	(Pearson’s	r	≥	0.995).	Lot-	to-	lot	consistency	was	high	for	all	assays	
and	comparisons	 (Pearson’s	 r	≥	0.998).	Reference	 ranges	 (2.5th-	97.5th	percentiles;	
n	=	200	 samples/assay)	 in	 seconds	were	 8.4-	10.6	 (PT	 Rec),	 18.2-	27.2	 (PT	Owren),	
23.6-	30.6	(aPTT),	24.1-	31.7	(aPTT	Lupus)	and	23.9-	33.2	(aPTT	Screen).
Conclusion:	Based	on	the	excellent	analytical	performance	and	good	agreement	with	
relevant	comparator	methods,	the	five	coagulation	assays	on	the	novel	cobas t 711 
and cobas t	511	analysers	are	suitable	for	routine	use	in	core	laboratories.
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and	 that	 relevant	 reference	 ranges	 are	 established,	 thus	 ensuring	
that	the	assays	are	suitable	for	routine	use	in	core	laboratories	and	
able	to	reliably	inform	clinical	decisions.26,27
This	 multicentre	 study	 evaluated	 the	 performance	 of	 the	 five	
new	 coagulation	 assays	 on	 the	 cobas t	 analysers.	 For	 each	 assay,	










Five	 assays	 (PT	 Rec,	 PT	 Owren,	 aPTT,	 aPTT	 Lupus	 and	 aPTT	
Screen;	Roche	Diagnostics	GmbH,	Mannheim,	Germany)	were	each	
evaluated	 for	 their	 analytical	 performance,	 and	 compared	 with	
existing	 methodologies/technologies	 (see	 below)	 in	 independent	






analyser.	 Anonymized	 human	 residual	 (3.2%	 [0.109M])	 sodium	
citrate	 plasma	 samples	 were	 used	 for	 all	 experiments;	 samples	
for	 reference	 range	 evaluation	 were	 sourced	 from	 a	 blood	 bank	




ple	 sources.	 Sample	 tubes	 were	 sourced	 from	 Becton-	Dickinson	




where	 necessary	 before	 study	 initiation	 according	 to	 local	 laws	




The	 PT	 Rec	 assay	 contains	 thromboplastin	 (recombinant	 human	


























while	 the	aPTT	Lupus	assay	has	 increased	sensitivity	 to	LA.	The	
aPTT	Screen	assay	is	designed	to	have	the	highest	sensitivity	to-
wards	UFH.
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2.3 | Analytical performance
Following	a	familiarization	phase,	within-	run	precision	of	each	assay	
was	 evaluated;	 reproducibility	 was	 also	 evaluated	 according	 to	
Clinical	Laboratory	Standards	Institute	(CLSI)	EP05-	A3	guidelines.30 















Method	 comparison	 was	 performed	 for	 each	 assay	 (cobas t 711 
analyser)	 vs	 the	 following	 comparator	methods,	 according	 to	CLSI	
EP09-	A3	 guidelines31:	 (a)	 PT	 Rec	 vs	 Innovin	 (Siemens	Healthcare,	
Marburg,	 Germany)	 on	 Sysmex	 CS-	5100	 or	 CS-	2000i	 (Sysmex,	
Kobe,	Japan);	(b)	PT	Owren	vs	Hepato-	Prest	(Diagnostica	Stago	SAS,	
Asnières-	sur-	Seine,	France)	on	Stago	STA-	R	Evolution	 (Diagnostica	




5100	 or	 CS-	2000i,	 and	 aPTT	 Lupus	 vs	 STA	 Cephascreen/STA-	LA	
(Diagnostica	 Stago	 SAS)	 on	 Stago	 STA-	R	 Evolution	 (performed	 in	




lot	 per	 site),	 using	 a	minimum	of	 120	 residual	 anonymized	 human	
plasma	 samples	 per	 assay,	 per	 site	 (representing	 the	 appropriate	
measuring	range).	The	measuring	ranges	tested	for	each	assay	were	
as	follows:	PT	Rec,	up	to	INR	5.5	or	approximately	60	seconds;	PT	
Owren,	 up	 to	 INR	 5.5	 or	 approximately	 150	seconds;	 aPTT,	 aPTT	
Screen	and	aPTT	Lupus,	up	to	175	seconds	for	each	assay.
2.5 | Equivalency of the cobas t analysers




















cylic	 acid,	 direct	 oral	 anticoagulants,	 phenprocoumon	 and	 warfa-
rin.	Experiments	were	performed	with	three	different	reagent	 lots	
(N	=	200;	n	≈67	samples	per	 lot).	Reference	 ranges	 for	each	assay	
were	 also	 determined	 using	 frozen	 0.109M/3.2%	 citrated	 sam-




sampling	and	measurement	 for	 reference	 range	samples	was	 typi-
cally	 1-	3	hours	 (Sarstedt	 tubes).	 To	 obtain	 frozen	 ranges	 (Sarstedt	
tubes),	these	samples	were	immediately	frozen	after	measurement	
of	 the	 Sarstedt	 fresh	 ranges.	 Both	 frozen	 sample	 types	 (Sarstedt	
and	Becton-	Dickinson)	were	measured	at	three	different	sites	after	
thawing	(one	reagent	lot	per	site).
2.8 | Sensitivity analysis of aPTT, aPTT 
Lupus and aPTT Screen assays to heparin and lupus 
anticoagulant
Sensitivity	 of	 the	 three	 new	 aPTT	 assays	 towards	 UFH	 and	 LA	
was	analysed.	The	presence	of	warfarin	 (UFH	analyses)	or	any	an-
ticoagulant	 (LA	analyses)	therapy	was	excluded	by	testing	with	PT	
(Thromborel	 S	 reagent),	 TT	 (BC	 Thrombin)	 and	 anti-	Xa	 (Hyphen	








Lupus	 anticoagulant-	positive	 plasma	 samples	 (n	=	96)	 were	
sourced	commercially	(Clinisys)	and	the	LA	ratio	determined	for	each	
sample	on	a	BCS	XP	system	with	LA1	and	LA2	reagents	(Siemens).	
The	sensitivity	of	the	three	aPTT	assays	on	a	cobas t 711 analyser 
was	assessed	by	comparison	with	the	LA	ratio.








Screen];	 total	 reproducibility	 [all	assays]	≤25.0%),	which	were	con-
sistent	with	published	guidelines.33
For	method	comparisons	(comparator	method,	cobas t	platform	
and	 lot-	to-	lot),	 slope	 and	 intercept	 were	 calculated	 according	 to	
Passing–Bablok	or	Deming,	 and	Pearson’s	 r	 correlation	 coefficient	
was	estimated;	analyses	were	based	on	INR	for	the	PT	Rec	and	PT	
Owren	assays,	and	on	seconds	for	the	aPTT,	aPTT	Lupus	and	aPTT	









fied	 acceptance	 criteria.	Across	 all	 five	 assays,	CVs	 for	within-	run	




and	from	0.3%	to	6.3%	on	the	cobas t 511 analyser.
3.2 | Method comparison
Method	 comparison	 experiments	 demonstrated	 good	 agree-
ment	for	each	assay	(cobas t	711)	vs	their	respective	comparator	
method	 according	 to	 prespecified	 criteria	 (specified	 in	 Product	
Specifications	 Document)	 based	 on	Deming	 regression	 analyses	
(Table	2).	For	each	comparison,	Pearson’s	correlation	coefficients	
(presented	 as	 a	 range	 across	 sites)	 confirmed	 an	 excellent	 cor-
relation	 between	 methods:	 PT	 Rec	 vs	 Innovin,	 r	=	0.988-	0.999;	
PT	 Owren	 vs	 Hepato-	Prest,	 r	=	0.990-	0.994;	 aPTT	 vs	 Actin	 FS,	
r	=	0.980-	0.986;	aPTT	vs	STA	Cephascreen,	r	=	0.819;	aPTT	Lupus	
vs	 Actin	 FSL,	 r	=	0.967-	0.987;	 aPTT	 Lupus	 vs	 STA	 Cephascreen,	
r	=	0.943;	 aPTT	 Lupus	 vs	 STA-	LA,	 r	=	0.958;	 aPTT	 Screen	 vs	




3.3 | Equivalency of cobas t 711 and cobas t 
511 analysers
For	each	of	the	five	assays	evaluated,	the	cobas t 711 and cobas t 
511	platforms	demonstrated	equivalence,	according	to	prespecified	




demonstrate	 constant	bias	 for	 the	 five	 assays,	with	 consistent	 re-
sults	for	the	two	sites.









Based	on	fresh	samples	 in	Sarstedt	tubes,	 reference	ranges	 (2.5th	to	
97.5th	percentiles	[90%	CI];	n	=	200	fresh	samples	per	assay)	in	seconds	
TABLE  1 Within-	run	precision	and	total	reproducibility	(across	all	four	sites)	of	the	five	coagulation	assays	on	the	cobas t 711 and cobas t 
511	analysers,	based	on	human	plasma	pools	(range	for	the	five	human	plasma	pools	is	presented)
Assay (s)
Within- run precision 
acceptance criteriaa(%)




Total reproducibility, range 
of % CV
cobas t 711 cobas t 511 cobas t 711 cobas t 511
PT	Rec CV	≤	3.0 0.2-	0.7 0.1-	0.4 CV	≤	25.0 1.9-	3.2 2.2-	3.7
PT	Owren CV	≤	3.0 0.3-	0.8 0.2-	0.6 CV	≤	25.0 1.5-	3.4 0.7-	2.2
aPTT CV	≤	4.0 0.2-	1.1 0.1-	0.8 CV	≤	25.0 0.9-	2.9 0.8-	3.8
aPTT	Lupus CV	≤	4.0 0.2-	1.3 0.3-	0.7 CV	≤	25.0 0.8-	3.1 0.3-	2.2
aPTT	Screen CV	≤	4.0 0.3-	1.2 0.2-	0.8 CV	≤	25.0 1.4-	3.4 0.8-	6.3
aPTT,	activated	partial	thromboplastin	time;	CV,	coefficient	of	variation;	PT,	prothrombin	time.
aUnit	for	acceptance	criteria	is	PT	in	seconds.
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Screen,	24.0	 (20.3-	24.6)	 to	34.3	 (33.6-	35.9).	 Similar	 reference	 ranges	
(90%	CI)	were	 also	obtained	using	 frozen	 samples	 stored	 in	Becton-	
Dickinson	tubes	(n	≥	150	samples	per	assay):	PT	Rec,	8.11	(7.84-	8.21)	to	
12.3	(11.4-	12.6);	PT	Owren,	18.8	(18.1-	18.9)	to	28.5	(27.1-	36.3);	aPTT,	
24.3	 (23.1-	24.5)	 to	 32.1	 (31.0-	34.6);	 aPTT	 Lupus,	 24.3	 (19.5-	24.7)	 to	
33.4	(32.4-	40.5);	aPTT	screen,	23.5	(21.7-	24.6)	to	39.8	(36.5-	57.7).
TABLE  2 Method	comparison:	cobas t	711	vs	comparator	device
Comparison Evaluation Acceptance criteriad
Freiburg Sheffield Debrecen Vienna Vienna
Lot 1 Lot 2 Lot 3 Lot 2 Lot 3
PT	Rec	vs	Innovina n 131 135 130
Slope	(Deming) 1.00 ± 0.10 1.008 1.036 0.900
Intercept NA 0.090 0.045 0.238
Pearson’s	r ≥0.900 0.999 0.997 0.988
Bias	at	1.0	INR 1	≤	0.15 0.097 0.081 0.138
PT	Owren	vs	Hepato-	Presta n 144 129 139
Slope	(Deming) 1.00 ± 0.10 0.853 0.845 0.833
Intercept NA 0.132 0.149 0.196
Pearson’s	r ≥0.900 0.994 0.993 0.990
Bias	at	1.0	INR 1	≤	0.15 −0.015 −0.006 0.029
aPTT	vs	Actin	FSb n 136 123 142 193
Slope	(Deming) 0.65-	1.35 1.037 1.061 1.040 0.953
Intercept NA 2.27 4.38 1.99 4.72
Pearson’s	r ≥0.850 0.986 0.982 0.980 0.980
aPTT	Lupus	vs	Actin	FSLb n 144 122 150 204
Slope	(Deming) 0.65-	1.35 1.041 1.286 1.126 1.098
Intercept NA 1.37 −5.86 −2.47 1.29
Pearson’s	r ≥0.850 0.967 0.983 0.987 0.982
aPTT	Screen	vs	Pathromtin	SLb n 132 125 139 183
Slope	(Deming) 0.65-	1.35 0.849 0.982 1.002 0.909
Intercept NA 4.27 −2.47 −2.37 3.32
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3.6 | Sensitivity of the aPTT, aPTT Lupus and 
aPTT Screen assays towards heparin and lupus 
anticoagulant
The	therapeutic	range	for	the	aPTT	assays	was	shorter	than	for	the	
comparator	 agents:	 lower	 (0.3	IU/mL)	 and	upper	 (0.7	IU/mL)	 limits	
for	 the	 coagulation	 time	 (seconds)	were	46.1-	57.4	 (aPTT)	 vs	 55.2-	
74.2	(Actin	FS);	53.9-	69.9	(aPTT	Lupus)	vs	55.7-	74.7	(Actin	FSL);	and	
56.4-	86.5	(aPTT	Screen)	vs	57.6-	79.8	(Pathromtin	SL).	aPTT	Screen	





urable	 clotting	 time.	The	 relative	differences	 in	 clotting	 time	 ratio	
were	0.97	 (aPTT	vs	Actin	FS),	0.95	 (aPTT	Lupus	vs	Actin	FSL)	and	
0.94	(aPTT	Screen	vs	Pathromtin	SL).
Activated	partial	 thromboplastin	 time	Lupus	demonstrated	 the	
greatest	 sensitivity	 towards	 LA	 antibodies,	 with	 the	 steepest	 re-
sponse	 to	 LA	 in	 LA-	positive	 plasma	 samples	 (Figure	1C).	 As	 with	
Assay Evaluation Acceptance criteriac
Freiburg Sheffield
Lot 1 Lot 2
PT	Reca n 129 135
Slope	(Passing–Bablok) 1.00 ± 0.10 1.006 0.984
Intercept NA 0.006 0.033
Pearson’s	r ≥0.900 1.000 1.000
Bias	at	1.0	INR NA 0.0119 0.0175
PT	Owrena n 145




aPTTb n 139 129
Slope	(Passing–Bablok) 1.00 ± 0.10 1.000 1.000
Intercept NA 0 0.100
Pearson’s	r ≥0.900 0.998 0.995




aPTT	Lupusb n 145 125
Slope	(Passing–Bablok) 1.00 ± 0.10 0.996 1.009
Intercept NA 0.139 −0.130
Pearson’s	r ≥0.900 0.999 0.999




aPTT	Screenb n 131 128
Slope	(Passing–Bablok) 1.00 ± 0.10 0.996 0.980
Intercept NA 0.507 0.604
Pearson’s	r ≥0.900 0.999 0.998











cobas t 711 and cobas t 511 analysers
























for	 monitoring	 anticoagulant	 therapy	 and	 for	 screening	 for	 spe-
cific	 coagulation	 abnormalities.	 For	 example,	 the	 PT	 Rec	 and	 PT	
TABLE  4 Lot-	to-	lot	comparison	on	the	cobas t 711 analyser
Assay Evaluation Acceptance criteriac
Freiburg Sheffield Debrecen
Lot 2 vs 1 Lot 3 vs 2 Lot 1 vs 3
PT	Reca n 129 135 129
Slope	(Passing–Bablok) 1.00 ± 0.10 1.000 1.000 1.008
Intercept NA 0.010 0.010 −0.013
Pearson’s	r ≥0.975 1.000 1.000 1.000
Bias	at	1.0	INR NA 0. 01 0. 01 −0.00476
PT	Owrena n 144 132d 135
Slope	(Passing–Bablok) 1.00 ± 0.10 1.002 0.989 1.000
Intercept NA −0.00243 0.0219 −0.0070
Pearson’s	r ≥0.950 1.000 1.000 1.000
Bias	at	1.0	INR NA 0.000 0.011 −0.007
aPTTb n 139 128 145
Slope	(Passing–Bablok) 1.00 ± 0.10 0.979 1.009 1.013
Intercept NA 0.704 0.156 −0.595
Pearson’s	r ≥0.975 0.999 0.999 0.999
Difference in median of normal 
range	samples
NA 0.30 0.40 0.30
aPTT	Lupusb n 147 125 151
Slope	(Passing–Bablok) 1.00 ± 0.10 0.943 1.014 1.031
Intercept NA 1.38 0.174 −1.04
Pearson’s	r ≥0.975 0.999 1.000 1.000
Difference in median of normal 
range	samples
NA 0.8 0.4 0.4
aPTT	Screenb n 131 129 144
Slope	(Passing–Bablok) 1.00 ± 0.10 1.023 0.987 0.992
Intercept NA −0.707 0.357 0.222
Pearson’s	r ≥0.975 0.998 0.999 0.999
Difference in median of normal 
range	samples
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Owren	 assays	 are	 intended	 to	 aid	 in	 the	 management	 of	 vitamin	
K	 antagonist	 therapy	 and	 PT	Rec	may	 also	 be	 used	 as	 a	 diagnos-
tic	 tool	 for	 liver	 function	 testing.17,23,28,38	Compared	with	PT	Rec,	
the	PT	Owren	assay	is	designed	to	be	less	sensitive	to	interference	
by	 lupus	antibodies	and	 is	 insensitive	to	variations	 in	 factor	V	and	
fibrinogen;	 the	PT	 clotting	 time	measured	with	both	assays	 is	 not	



























aPTT	Screen	assay	has	 the	highest	 sensitivity	 towards	UFH,	 com-
pared	with	the	aPTT	and	aPTT	Lupus	assays.
Importantly,	 measurements	 with	 each	 assay	 showed	 good	
agreement	when	performed	on	 the	cobas t 711 and cobas t 511 
analysers,	thus	demonstrating	equivalence	between	the	two	plat-
forms.	 Both	 systems	 are	 built	 from	 functionally	 identical	 com-
ponents	 and	 implement	 identical	 assay	 processes	 using	 identical	
reagents	and	disposables.	The	systems	provide	automatic	reagent	
reconstitution,	continuous	loading	of	all	samples,	reagents	and	cu-
vettes,	 and	a	high	 reagent	 storage	 capacity	 and	are	 thus	 aligned	
with	 the	 need	 for	 efficient	 workflow	 in	 core	 laboratories;	 the	
main	 difference	 between	 platforms	 is	 the	 level	 of	 throughput,	
with	 the	 cobas t	 711	 platform	 being	 classed	 as	 high-	throughput	
(390	tests/h)	and	the	cobas t	511	platform	as	medium	throughput	
(195	tests/h).	Laboratory	coagulation	testing	accounts	for	around	





ease.	 Therefore,	 improvements	 in	 throughput	 and	 efficiency	 are	
highly	 desirable	 and	 can	 result	 in	 significant	 capacity	 gains	 and	
cost	savings.
Strengths	of	the	study	include	the	multicentre	design	(includ-
ing	 four	 core	 laboratories	 in	 different	 European	 countries)	 and	
adherence	to	CLSI	guidelines.	Furthermore,	method	comparisons	
were	 performed	 against	 relevant	 commercially	 available	 assays/
platforms	 and	 reference	 ranges	were	 established	 for	 each	 assay	
using	samples	from	200	apparently	healthy	volunteers.	Although	
not	 a	 limitation	 of	 the	 study	 design,	 which	 aimed	 to	 assess	 the	
analytical	performance	of	the	assays	and	their	interchangeability	
with	 existing	 commercially	 available	 methods,	 the	 authors	 note	
that	this	study	did	not	aim	to	assess	the	clinical	performance	of	the	
assays	on	the	cobas t	analysers	in	terms	of	their	ability	to	detect	
abnormalities	 in	 coagulation	 factors,	 or	 assess	 therapeutic	 drug	





lation	assays	on	the	novel	cobas t 711 and cobas t 511 analysers are 
suitable	for	routine	use	in	core	laboratories.
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